Enteric-type thymic adenocarcinomas are rare histological variants with limited treatment options. We report the case of a 56-year-old woman with stage IVB enteric-type thymic adenocarcinoma who was treated with lenvatinib. The patient underwent chemoradiotherapy and subsequently received lenvatinib for local recurrence. Despite the patient receiving a low dosage owing to side effects, the size of the recurrent lesions decreased. However, 5 months later, new brain metastases and carcinomatous meningitis developed, and the patient eventually succumbed to cancer. This case suggests that lenvatinib may be an effective treatment for enteric-type adenocarcinomas. However, at low doses, its efficacy may be limited to intracranial lesions.
Hosokawa et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: